Search

Your search keyword '"Mellemkjær L"' showing total 468 results
Start Over Author "Mellemkjær L"
468 results on '"Mellemkjær L"'

1. Validation of an Algorithm to Ascertain Late Breast Cancer Recurrence Using Danish Medical Registries

Author

Pedersen RN, Öztürk B, Mellemkjær L, Friis S, Tramm T, Nørgaard M, and Cronin-Fenton DP

Subjects
algorithm, late breast cancer recurrence, breast cancer neoplasm, ppv, sensitivity, Infectious and parasitic diseases, RC109-216
Abstract

Rikke Nørgaard Pedersen,1 Buket Öztürk,1 Lene Mellemkjær,2 Søren Friis,2 Trine Tramm,3 Mette Nørgaard,1 Deirdre P Cronin-Fenton1 1Department of Clinical Epidemiology, Aarhus University, Aarhus, Denmark; 2Danish Cancer Society Research Center, Copenhagen, Denmark; 3Department of Pathology, Aarhus University Hospital, Aarhus, DenmarkCorrespondence: Rikke Nørgaard PedersenDepartment of Clinical Epidemiology, Aarhus University, Aarhus, DenmarkTel +4587167212Email rikp@clin.au.dkPurpose: About 70% of women with breast cancer survive at least 10 years after diagnosis. We constructed an algorithm to ascertain late breast cancer recurrence—which we define as breast cancer that recurs 10 years or more after primary diagnosis (excluding contralateral breast cancers)—using Danish nationwide medical registries. We used clinical information recorded in medical records as a reference standard.Methods: Using the Danish Breast Cancer Group clinical database, we ascertained data on 21,134 women who survived recurrence-free 10 years or more after incident stage I–III breast cancer diagnosed in 1987– 2004. We used a combination of Danish registries to construct the algorithm—the Danish National Patient Registry for information on diagnostic, therapeutic and procedural codes; and cancer diagnoses from the Danish Pathology Registry, the Danish Cancer Registry and the Contralateral Breast Cancer database. To estimate the positive predictive value (PPV), we selected 105 patients who, according to our algorithm, had late recurrence diagnosed at Aarhus University Hospital. To estimate the sensitivity, specificity and negative predictive value (NPV), we selected 114 patients diagnosed with primary breast cancer at Aalborg University Hospital. We abstracted clinical information on late recurrence for patients with medical record-confirmed late recurrence at Aarhus University Hospital.Results: Our algorithm had a PPV of late recurrence of 85.7% (95% CI: 77.5– 91.3%), a sensitivity of 100.0% (95% CI, 39.8– 100.0%), a specificity of 97.3 (95% CI, 92.2– 99.4) and a NPV of 100% (95% CI, 96.6– 100.0%).Conclusion: Our algorithm for late recurrence showed a moderate to high PPV and high sensitivity, specificity and negative predictive value. The algorithm could be an important tool for future studies of late breast cancer recurrence.Keywords: algorithm, late breast cancer recurrence, breast cancer neoplasm, PPV, sensitivity

Published
2020

3. Risk for contralateral breast cancer among carriers of the CHEK2*1100delC mutation in the WECARE Study.

Author

Mellemkjaer, L, Dahl, C, Olsen, JH, Bertelsen, L, Guldberg, P, Christensen, J, Børresen-Dale, A-L, Stovall, M, Langholz, B, Bernstein, L, Lynch, CF, Malone, KE, Haile, RW, Andersson, M, Thomas, DC, Concannon, P, Capanu, M, Boice, JD, WECARE Study Collaborative Group, and Bernstein, JL

Subjects
WECARE Study Collaborative Group, Humans, Breast Neoplasms, Protein-Serine-Threonine Kinases, SEER Program, Risk Factors, Case-Control Studies, Genotype, Germ-Line Mutation, Middle Aged, Female, Checkpoint Kinase 2, Oncology & Carcinogenesis, Oncology and Carcinogenesis, Public Health and Health Services
Abstract

The protein encoded by the CHEK2 gene is involved in cellular repair of DNA damage. The truncating mutation, CHEK2*1100delC, seems to increase the risk for breast cancer. We investigated whether the CHEK2*1100delC mutation carrier status increases the risk for asynchronous contralateral breast cancer (CBC) and whether it interacts with radiation therapy (RT) or chemotherapy in regard to CBC risk. The germline mutation frequency was assessed in 708 women with CBC and 1395 women with unilateral breast cancer (UBC) in the Women's Environment, Cancer and Radiation Epidemiology (WECARE) Study whose first primary breast cancer was diagnosed before age 55 years and during 1985--1999. Seven women with CBC (1.0%) and 10 women with UBC (0.7%) were CHEK2*1100delC variant carriers (rate ratio (RR)=1.8, 95% confidence interval (CI)=0.6-5.4 for CBC vs UBC). Carriers who received RT for their first breast cancer, compared with non-carriers not treated with RT, had an RR of developing CBC of 2.6 (95% CI=0.8-8.7). We found no significant associations between the CHEK2*1100delC mutation and CBC overall or among those treated with RT. However, the sampling variability was such that modest increases in risk could not be excluded. Nonetheless, because this is a rare mutation, it is unlikely to explain a major fraction of CBC in the population.

Published
2008

4. Risk for contralateral breast cancer among carriers of the CHEK2*1100delC mutation in the WECARE Study

Author

Mellemkjær, L, Dahl, C, Olsen, JH, Bertelsen, L, Guldberg, P, Christensen, J, Børresen-Dale, A-L, Stovall, M, Langholz, B, Bernstein, L, Lynch, CF, Malone, KE, Haile, RW, Andersson, M, Thomas, DC, Concannon, P, Capanu, M, Boice, JD, The WECARE Study Collaborative Group, and Bernstein, JL

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Breast Cancer, Clinical Research, Prevention, Cancer, Genetics, Breast Neoplasms, Case-Control Studies, Checkpoint Kinase 2, Female, Genotype, Germ-Line Mutation, Humans, Middle Aged, Protein Serine-Threonine Kinases, Risk Factors, SEER Program, WECARE Study Collaborative Group, Public Health and Health Services, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

The protein encoded by the CHEK2 gene is involved in cellular repair of DNA damage. The truncating mutation, CHEK2*1100delC, seems to increase the risk for breast cancer. We investigated whether the CHEK2*1100delC mutation carrier status increases the risk for asynchronous contralateral breast cancer (CBC) and whether it interacts with radiation therapy (RT) or chemotherapy in regard to CBC risk. The germline mutation frequency was assessed in 708 women with CBC and 1395 women with unilateral breast cancer (UBC) in the Women's Environment, Cancer and Radiation Epidemiology (WECARE) Study whose first primary breast cancer was diagnosed before age 55 years and during 1985--1999. Seven women with CBC (1.0%) and 10 women with UBC (0.7%) were CHEK2*1100delC variant carriers (rate ratio (RR)=1.8, 95% confidence interval (CI)=0.6-5.4 for CBC vs UBC). Carriers who received RT for their first breast cancer, compared with non-carriers not treated with RT, had an RR of developing CBC of 2.6 (95% CI=0.8-8.7). We found no significant associations between the CHEK2*1100delC mutation and CBC overall or among those treated with RT. However, the sampling variability was such that modest increases in risk could not be excluded. Nonetheless, because this is a rare mutation, it is unlikely to explain a major fraction of CBC in the population.

Published
2008

6. A body shape index (ABSI) is associated inversely with post-menopausal progesterone-receptor-negative breast cancer risk in a large European cohort

Author

Christakoudi, S, Tsilidis, KK, Dossus, L, Rinaldi, S, Weiderpass, E, Antoniussen, CS, Dahm, CC, Tjønneland, A, Mellemkjær, L, Katzke, V, Kaaks, R, Schulze, MB, Masala, G, Grioni, S, Panico, S, Tumino, R, Sacerdote, C, May, AM, Monninkhof, EM, Quirós, JR, Bonet, C, Sánchez, M-J, Amiano, P, Chirlaque, M-D, Guevara, M, Rosendahl, AH, Stocks, T, Perez-Cornago, A, Tin Tin, S, Heath, AK, Aglago, EK, Peruchet-Noray, L, Freisling, H, and Riboli, E

Subjects
Breast Neoplasms/complications, Somatotypes, Hip Size, Triple Negative Breast Neoplasms/complications, Waist Size, Middle Aged, Body Mass Index, Postmenopause, ABSI, Body shape, Breast cancer, Risk Factors, Humans, Female, Prospective Studies, Obesity, Progesterone
Abstract

BACKGROUND: Associations of body shape with breast cancer risk, independent of body size, are unclear because waist and hip circumferences are correlated strongly positively with body mass index (BMI).METHODS: We evaluated body shape with the allometric "a body shape index" (ABSI) and hip index (HI), which compare waist and hip circumferences, correspondingly, among individuals with the same weight and height. We examined associations of ABSI, HI, and BMI (per one standard deviation increment) with breast cancer overall, and according to menopausal status at baseline, age at diagnosis, and oestrogen and progesterone receptor status (ER+/-PR+/-) in multivariable Cox proportional hazards models using data from the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort.RESULTS: During a mean follow-up of 14.0 years, 9011 incident breast cancers were diagnosed among 218,276 women. Although there was little evidence for association of ABSI with breast cancer overall (hazard ratio HR = 0.984; 95% confidence interval: 0.961-1.007), we found borderline inverse associations for post-menopausal women (HR = 0.971; 0.942-1.000; n = 5268 cases) and breast cancers diagnosed at age ≥ 55 years (HR = 0.976; 0.951-1.002; n = 7043) and clear inverse associations for ER + PR- subtypes (HR = 0.894; 0.822-0.971; n = 726) and ER-PR- subtypes (HR = 0.906; 0.835-0.983 n = 759). There were no material associations with HI. BMI was associated strongly positively with breast cancer overall (HR = 1.074; 1.049-1.098), for post-menopausal women (HR = 1.117; 1.085-1.150), for cancers diagnosed at age ≥ 55 years (HR = 1.104; 1.076-1.132), and for ER + PR + subtypes (HR = 1.122; 1.080-1.165; n = 3101), but not for PR- subtypes.CONCLUSIONS: In the EPIC cohort, abdominal obesity evaluated with ABSI was not associated with breast cancer risk overall but was associated inversely with the risk of post-menopausal PR- breast cancer. Our findings require validation in other cohorts and with a larger number of PR- breast cancer cases.

Published
2023

8. Metabolically defined body size and body shape phenotypes and risk of postmenopausal breast cancer in the European Prospective Investigation into Cancer and Nutrition

Author

Mahamat‐Saleh, Y., primary, Rinaldi, S., additional, Kaaks, R., additional, Biessy, C., additional, Gonzalez‐Gil, E. M., additional, Murphy, N., additional, Le Cornet, C., additional, Huerta, J. M., additional, Sieri, S., additional, Tjønneland, A., additional, Mellemkjær, L., additional, Guevara, M., additional, Overvad, K., additional, Perez‐Cornago, A., additional, Tin Tin, S., additional, Padroni, L., additional, Simeon, V., additional, Masala, G., additional, May, A., additional, Monninkhof, E., additional, Christakoudi, S., additional, Heath, A. K., additional, Tsilidis, K., additional, Agudo, A., additional, Schulze, M. B., additional, Rothwell, J., additional, Cadeau, C., additional, Severi, S., additional, Weiderpass, E., additional, Gunter, M. J., additional, and Dossus, L., additional

Published
2023
Full Text
View/download PDF

9. Metabolically defined body size and body shape phenotypes and risk of postmenopausal breast cancer in the European Prospective Investigation into Cancer and Nutrition

Author

Epi Kanker, Cancer, JC onderzoeksprogramma Kanker, Epi Kanker Team C, Mahamat-Saleh, Y., Rinaldi, S., Kaaks, R., Biessy, C., Gonzalez-Gil, E. M., Murphy, N., Le Cornet, C., Huerta, J. M., Sieri, S., Tjønneland, A., Mellemkjær, L., Guevara, M., Overvad, K., Perez-Cornago, A., Tin Tin, S., Padroni, L., Simeon, V., Masala, G., May, A., Monninkhof, E., Christakoudi, S., Heath, A. K., Tsilidis, K., Agudo, A., Schulze, M. B., Rothwell, J., Cadeau, C., Severi, S., Weiderpass, E., Gunter, M. J., Dossus, L., Epi Kanker, Cancer, JC onderzoeksprogramma Kanker, Epi Kanker Team C, Mahamat-Saleh, Y., Rinaldi, S., Kaaks, R., Biessy, C., Gonzalez-Gil, E. M., Murphy, N., Le Cornet, C., Huerta, J. M., Sieri, S., Tjønneland, A., Mellemkjær, L., Guevara, M., Overvad, K., Perez-Cornago, A., Tin Tin, S., Padroni, L., Simeon, V., Masala, G., May, A., Monninkhof, E., Christakoudi, S., Heath, A. K., Tsilidis, K., Agudo, A., Schulze, M. B., Rothwell, J., Cadeau, C., Severi, S., Weiderpass, E., Gunter, M. J., and Dossus, L.

Published
2023

10. Metabolically defined body size and body shape phenotypes and risk of postmenopausal breast cancer in the European Prospective Investigation into Cancer and Nutrition

Author

Mahamat-Saleh, Y., Rinaldi, S., Kaaks, R., Biessy, C., Gonzalez-Gil, E. M., Murphy, N., Le Cornet, C., Huerta, J. M., Sieri, S., Tjønneland, A., Mellemkjær, L., Guevara, M., Overvad, K., Perez-Cornago, A., Tin Tin, S., Padroni, L., Simeon, V., Masala, G., May, A., Monninkhof, E., Christakoudi, S., Heath, A. K., Tsilidis, K., Agudo, A., Schulze, M. B., Rothwell, J., Cadeau, C., Severi, S., Weiderpass, E., Gunter, M. J., Dossus, L., Mahamat-Saleh, Y., Rinaldi, S., Kaaks, R., Biessy, C., Gonzalez-Gil, E. M., Murphy, N., Le Cornet, C., Huerta, J. M., Sieri, S., Tjønneland, A., Mellemkjær, L., Guevara, M., Overvad, K., Perez-Cornago, A., Tin Tin, S., Padroni, L., Simeon, V., Masala, G., May, A., Monninkhof, E., Christakoudi, S., Heath, A. K., Tsilidis, K., Agudo, A., Schulze, M. B., Rothwell, J., Cadeau, C., Severi, S., Weiderpass, E., Gunter, M. J., and Dossus, L.

Abstract

Background: Excess body fatness and hyperinsulinemia are both associated with an increased risk of postmenopausal breast cancer. However, whether women with high body fatness but normal insulin levels or those with normal body fatness and high levels of insulin are at elevated risk of breast cancer is not known. We investigated the associations of metabolically defined body size and shape phenotypes with the risk of postmenopausal breast cancer in a nested case–control study within the European Prospective Investigation into Cancer and Nutrition. Methods: Concentrations of C-peptide—a marker for insulin secretion—were measured at inclusion prior to cancer diagnosis in serum from 610 incident postmenopausal breast cancer cases and 1130 matched controls. C-peptide concentrations among the control participants were used to define metabolically healthy (MH; in first tertile) and metabolically unhealthy (MU; >1st tertile) status. We created four metabolic health/body size phenotype categories by combining the metabolic health definitions with normal weight (NW; BMI < 25 kg/m2, or WC < 80 cm, or WHR < 0.8) and overweight or obese (OW/OB; BMI ≥ 25 kg/m2, or WC ≥ 80 cm, or WHR ≥ 0.8) status for each of the three anthropometric measures separately: (1) MHNW, (2) MHOW/OB, (3) MUNW, and (4) MUOW/OB. Conditional logistic regression was used to compute odds ratios (ORs) and 95% confidence intervals (CIs). Results: Women classified as MUOW/OB were at higher risk of postmenopausal breast cancer compared to MHNW women considering BMI (OR = 1.58, 95% CI = 1.14–2.19) and WC (OR = 1.51, 95% CI = 1.09–2.08) cut points and there was also a suggestive increased risk for the WHR (OR = 1.29, 95% CI = 0.94–1.77) definition. Conversely, women with the MHOW/OB and MUNW were not at statistically significant elevated risk of postmenopausal breast cancer risk compared to MHNW women. Conclusion: These findings suggest that being overweight or obese and metabol

Published
2023

11. Association of Mediterranean diet with survival after breast cancer diagnosis in women from nine European countries: results from the EPIC cohort study

Author

Castro-Espin, C, Bonet, C, Crous-Bou, M, Nadal-Zaragoza, N, Tjønneland, A, Mellemkjær, L, Hajji-Louati, M, Truong, T, Katzke, V, Le Cornet, C, Schulze, MB, Jannasch, F, Masala, G, Sieri, S, Panico, S, Di Girolamo, C, Skeie, G, Borch, KB, Olsen, KS, Sánchez, M-J, Amiano, P, Chirlaque, M-D, Guevara, M, Sund, M, Bodén, S, Gunter, MJ, Gonzalez-Gil, EM, Weiderpass, E, Aguilera-Buenosvinos, I, Tsilidis, KK, Heath, AK, Aune, D, Dossus, L, and Agudo, A

Subjects
Näringslära, Folkhälsovetenskap, global hälsa, socialmedicin och epidemiologi, Nutrition and Dietetics, Breast cancer, Cancer survivors, Mediterranean diet, Public Health, Global Health, Social Medicine and Epidemiology, Dietary patterns, Prospective studies
Abstract

BACKGROUND: The Mediterranean diet has been associated with lower risk of breast cancer (BC) but evidence from prospective studies on the role of Mediterranean diet on BC survival remains sparse and conflicting. We aimed to investigate whether adherence to Mediterranean diet prior to diagnosis is associated with overall and BC-specific mortality. METHODS: A total of 13,270 incident breast cancer cases were identified from an initial sample of 318,686 women in 9 countries from the European Prospective Investigation into Cancer and Nutrition (EPIC) study. Adherence to Mediterranean diet was estimated through the adapted relative Mediterranean diet (arMED), a 16-point score that includes 8 key components of the Mediterranean diet and excludes alcohol. The degree of adherence to arMED was classified as low (score 0-5), medium (score 6-8), and high (score 9-16). Multivariable Cox proportional hazards models were used to analyze the association between the arMED score and overall mortality, and Fine-Gray competing risks models were applied for BC-specific mortality. RESULTS: After a mean follow-up of 8.6 years from diagnosis, 2340 women died, including 1475 from breast cancer. Among all BC survivors, low compared to medium adherence to arMED score was associated with a 13% higher risk of all-cause mortality (HR 1.13, 95%CI 1.01-1.26). High compared to medium adherence to arMED showed a non-statistically significant association (HR 0.94; 95% CI 0.84-1.05). With no statistically significant departures from linearity, on a continuous scale, a 3-unit increase in the arMED score was associated with an 8% reduced risk of overall mortality (HR3-unit 0.92, 95% CI: 0.87-0.97). This result sustained when restricted to postmenopausal women and was stronger among metastatic BC cases (HR3-unit 0.81, 95% CI: 0.72-0.91). CONCLUSIONS: Consuming a Mediterranean diet before BC diagnosis may improve long-term prognosis, particularly after menopause and in cases of metastatic breast cancer. Well-designed dietary interventions are needed to confirm these findings and define specific dietary recommendations.

Published
2023

13. Cancer in pregnancy increases the risk of venous thromboembolism:a nationwide cohort study

Author

Greiber, I. K., Mikkelsen, A. P., Karlsen, M. A., Storgaard, L., Viuff, J. H., Mellemkjær, L., Hjortshøj, C. S., Lidegaard, Greiber, I. K., Mikkelsen, A. P., Karlsen, M. A., Storgaard, L., Viuff, J. H., Mellemkjær, L., Hjortshøj, C. S., and Lidegaard

Abstract

Objective: To investigate if cancer in pregnancy causes a higher risk of venous thromboembolism (VTE) during pregnancy and postpartum compared with pregnant women without cancer. Design: A historical prospective cohort study using data from nationwide registries. Setting and population: We assessed all pregnancies in Denmark between 1 January 1977 and 31 December 2017. Methods: We linked information concerning cancer diagnosis, pregnancy and VTE diagnosis and potential confounders. Event rates of VTE for women with pre-pregnancy cancer, cancer in pregnancy and without cancer were calculated per 10 000 pregnancies and compared using logistic regression analysis. Main outcome measures: Occurrence of VTE during pregnancy or the postpartum period. Results: A total of 3 581 214 pregnancies were included in the study and we found 1330 women with cancer in pregnancy. In pregnant women with cancer, the event rate of VTE was 75.2 per 10 000 pregnancies compared with 10.7 per 10 000 pregnancies in the no cancer group. The findings correspond to an increased adjusted odds ratio of 6.50 (95% CI3.5–12.1) in the cancer in pregnancy group in comparison with the no cancer group. Conclusions: Women with cancer in pregnancy have a markedly higher risk of pregnancy-associated VTE compared with women without cancer. In pregnancy-related VTE risk assessment, the presence of cancer alone may be sufficient to indicate thromboprophylaxis. Tweetable abstract: Cancer in pregnancy increases the risk of VTE during pregnancy and the postpartum period.

Published
2021

15. Cancer in pregnancy increases the risk of venous thromboembolism: a nationwide cohort study.

Author

Greiber, IK, Mikkelsen, AP, Karlsen, MA, Storgaard, L, Viuff, JH, Mellemkjær, L, Hjortshøj, CS, Lidegaard, Ø, Greiber, I K, Mikkelsen, A P, Karlsen, M A, Viuff, J H, Mellemkjaer, L, and Hjortshøj, C S

Subjects
THROMBOEMBOLISM, HIGH-risk pregnancy, PREGNANCY, LOGISTIC regression analysis, PREGNANT women, VEINS, ACQUISITION of data, PUERPERAL disorders, RISK assessment, PREGNANCY complications, BLOOD diseases, RESEARCH funding, LONGITUDINAL method
Abstract

Objective: To investigate if cancer in pregnancy causes a higher risk of venous thromboembolism (VTE) during pregnancy and postpartum compared with pregnant women without cancer.Design: A historical prospective cohort study using data from nationwide registries.Setting and Population: We assessed all pregnancies in Denmark between 1 January 1977 and 31 December 2017.Methods: We linked information concerning cancer diagnosis, pregnancy and VTE diagnosis and potential confounders. Event rates of VTE for women with pre-pregnancy cancer, cancer in pregnancy and without cancer were calculated per 10 000 pregnancies and compared using logistic regression analysis.Main Outcome Measures: Occurrence of VTE during pregnancy or the postpartum period.Results: A total of 3 581 214 pregnancies were included in the study and we found 1330 women with cancer in pregnancy. In pregnant women with cancer, the event rate of VTE was 75.2 per 10 000 pregnancies compared with 10.7 per 10 000 pregnancies in the no cancer group. The findings correspond to an increased adjusted odds ratio of 6.50 (95% CI3.5-12.1) in the cancer in pregnancy group in comparison with the no cancer group.Conclusions: Women with cancer in pregnancy have a markedly higher risk of pregnancy-associated VTE compared with women without cancer. In pregnancy-related VTE risk assessment, the presence of cancer alone may be sufficient to indicate thromboprophylaxis.Tweetable Abstract: Cancer in pregnancy increases the risk of VTE during pregnancy and the postpartum period. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

30. Second primary malignancies among women with uterine sarcoma

Author

Koivisto-Korander R, Scelo G, Ferro G, Mellemkjaer L, Hemminki K, Weiderpass E, Tamaro S, Pompe-Kirn V, Tracey E, Brewster D, Kliewer E, Tonita J, Kee-Seng C, Jonasson J, Martos C, Brennan P, Straif K, and Pukkala E

Subjects
Uterine leiomyosarcoma, Multi-centre cohort study, Endometrial stromal sarcoma, Second primary cancer, Uterine sarcoma
Abstract

Objective. Uterine sarcomas (US) are rare malignancies with unclear aetiology. Studies on uterine sarcomas in the setting of second primary malignant tumours can provide clues to aetiology and identify side effects of different treatments. Methods. A cohort of 8606 cases of US was extracted from the data from 13 cancer registries and followed for second primary cancers within the period 1943-2000. Standardized incidence ratios (SIRs) were calculated, and Poisson regression analyses were performed. Results. There were 499 cancer cases observed after a first diagnosis of US (SIR 1.26, 95%CI 1.16-1.38). SIRs were elevated for cancers of the mouth and pharynx (2.16, 95%CI 1.15-3.69), colorectum (1.60, 95%CI 1.28-1.98), lung (1.73, 95%CI 1.27-2.29), breast (1.25, 95%CI 1.05-1.49), urinary bladder (1.74, 95%CI 1.02-2.79), kidney (2.00, 95%CI 1.24-3.06), thyroid gland (2.74, 95%CI 1.42-4.79), and soft tissue sarcoma (5.23, 95%CI 2.51-9.62). The risk of breast cancer increased along with increasing age of US diagnosis (p trend 0.040). The risk of kidney cancer increased along with decreasing age of US diagnosis (p trend 0.004) and short time since the US diagnosis (p trend 0.018). Conclusions. Our study demonstrated increased risk of certain cancers following a diagnosis of US. The elevated risk for breast cancer may indicate shared hormonal aetiology, while the increased risk of colorectal and bladder cancers after US may be caused by radiation therapy of US. The clustering of smoking-related cancers after US is worth exploring in the future. (c) 2012 Elsevier Inc. All rights reserved.

Published
2012

32. The intrauterine origin of male breast cancer: a birth order study in Denmark

Author

Sorensen, HT Olsen, ML Mellemkjaer, L Lagiou, P Olsen, JH Olsen, J

Subjects
skin and connective tissue diseases
Abstract

First pregnancies are known to have higher oestrogen levels than later ones and first-born women are at increased breast cancer risk compared with later-born women. We hypothesized that a birth order effect might be even more evident in male breast cancer patients, in whom oestrogens in adult life are generally low. In a population-based study in Denmark involving 77 male breast cancer patients and 288 population controls, first-born men compared with later-born men had a relative risk of 1.71 for the disease (95% confidence interval (Cl) 1.00-2.92). This result is in line with that seen in female breast cancer cases and indicates that male breast cancer may have roots in the intrauterine life, oestrogens being a likely mediator. (c) 2005 Lippincott Williams & Wilkins.

Published
2005

40. Birth weight and risk of early-onset breast cancer (Denmark)

Author

Mellemkjær, L., Mette Lena Olsen, Henrik Toft Sørensen, Ane Marie Thulstrup, Jørn Olsen, and Olsen, J. H.

Subjects
Adult, Risk, Case-Control Studies, Denmark, Population Surveillance, Birth Weight, Humans, Breast Neoplasms, Female, Age of Onset, Middle Aged, Aged
Abstract

To investigate if birth weight is associated with early-onset breast cancer. The mechanism behind an association with high birth weight could be the link between fetal growth and estrogens in utero.We conducted a population-based case-control study in Denmark including 881 women with breast cancer diagnosed before the age of 40 years and 3,423 age-matched controls. Information concerning birth weight and other birth-related variables was obtained from midwife reports.The risk of early-onset breast cancer was increased 1.25 times (95% CI 1.00-2.51) for birth weights above 4,000 g and 1.59 times (95% CI 1.00-1.55) for birth weights below 2,500 g in comparison with birthweights of 3,000-3,499 g.The finding that high birth weight is associated with breast cancer is compatible with the hypothesis that level of estrogen during pregnancy is related to breast cancer in early adult life. The finding that low birth weight is also associated with breast cancer may indicate that other characteristics of the fetal environment may be important for breast cancer in early adult life.

Published
2003

50. The impact of M-component type and immunoglobulin concentration on the risk of malignant transformation in patients with monoclonal gammopathy of undetermined significance

Author

Gregersen, H., Mellemkjær, L., Ibsen, J. S., Jens Frederik Dahlerup, Thomassen, L., and Henrik Toft Sørensen

Subjects
Adult, Aged, 80 and over, Male, Adolescent, Infant, Newborn, Paraproteinemias, Infant, Middle Aged, Immunoglobulin Isotypes, Cell Transformation, Neoplastic, Risk Factors, Child, Preschool, Humans, Female, Poisson Distribution, Child, Aged, Paraproteins
Published
2001

Catalog

Books, media, physical & digital resources
See catalog results